Compare ORIS & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIS | CNSP |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.8M |
| IPO Year | 2024 | 2019 |
| Metric | ORIS | CNSP |
|---|---|---|
| Price | $1.52 | $5.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 180.5K | 20.8K |
| Earning Date | 04-30-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $12,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $163.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.14 | $4.93 |
| 52 Week High | $57.00 | $114.00 |
| Indicator | ORIS | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 96.29 | 30.95 |
| Support Level | $0.06 | $6.00 |
| Resistance Level | $0.11 | $6.17 |
| Average True Range (ATR) | 0.05 | 0.61 |
| MACD | 0.13 | -0.17 |
| Stochastic Oscillator | 85.91 | 1.08 |
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.